The United States’ national infant acne vaccine program is getting some new attention.

The CDC announced on Thursday that the first vaccine candidate has been approved by the Food and Drug Administration, which will send it to patients for testing in April.

The vaccine has been in the works for years, and the Centers for Disease Control and Prevention (CDC) said that the approval means that the drug can now be given to millions of people without causing adverse reactions.

The FDA has previously approved two other drugs to treat infant acne, but neither has been tested on humans.

“We’ve had a long and successful path to approval of an immunotherapy that works in our infants and children,” CDC Director Dr. Tom Frieden said in a statement.

“We’re excited to be able to begin the new phase of the vaccine’s development.”

The vaccine, called Pembrolizumab, targets a protein called CD31, which can cause the growth of new acne lesions in infants and toddlers.

The disease is the leading cause of blindness in children.

The drug targets the protein so that it binds to it and blocks its activity.

Pembolizumabs currently work in animals but can only be administered to humans because of a lack of a vaccine.

The CDC also said that its Pembralizumacin vaccine candidate is currently being evaluated by researchers in Japan and the United Kingdom, and it will be sent to a large clinical trial in the coming months.

The study is aimed at testing whether the vaccine could reduce the risk of death or serious complications.

Pembrolitzumab is being developed by Pfizer, one of the world’s largest drugmakers.

Its drug was approved in June and the company said it will receive more money from the government than any other drug.